Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 9/20 | 0.52 |
| ▸ | PTPN1 | P18031 | 6/20 | 0.52 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.40 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.40 |
| ▸ | TAS1R2 | Q8TE23 | 1/20 | 0.40 |
| ▸ | CES2 | O00748 | 1/20 | 0.40 |
| ▸ | CES1 | P23141 | 1/20 | 0.40 |
| ▸ | TPMT | P51580 | 1/20 | 0.39 |
| ▸ | GPR139 | Q6DWJ6 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | METAP2 | P50579 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1198757 | 0.86 | GSK3B (0.61) | GSK3BPTPN1TPMTRAB9A | |
| SCHEMBL976560 | 0.86 | PTPN1 (0.61) | GSK3BPTPN1CES2CES1 | |
| SCHEMBL3713101 | 0.82 | CES2 (0.41) | TAS1R3TAS1R1TAS1R2CES2CES1 | |
| SCHEMBL30512212 | 0.81 | TAS1R3 (0.43) | TAS1R3TAS1R1TAS1R2CES2CES1 | |
| SCHEMBL12780435 | 0.81 | TAS1R3 (0.43) | TAS1R3TAS1R1TAS1R2CES2CES1 | |
| SCHEMBL3147239 | 0.79 | MEN1 (0.42) | GSK3BTAS1R3TAS1R1TAS1R2CES2 | |
| SCHEMBL5190490 | 0.78 | PTPN1 (0.53) | GSK3BPTPN1CES2CES1 | |
| SCHEMBL5050069 | 0.78 | GSK3B (0.53) | GSK3BPTPN1TPMTGPR139RAB9A | |
| SCHEMBL12876821 | 0.77 | GSK3B (0.52) | GSK3BPTPN1CES2CES1TPMT | |
| SCHEMBL766063 | 0.77 | GSK3B (0.56) | GSK3BPTPN1CES2MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9802927-B2 | Oxadiazine compounds and methods of use thereof | DENALI THERAPEUTICS, INC. (US) | 2017-10-31 | — | — | US | disclosed |
| US-9802927-B2 | Oxadiazine compounds and methods of use thereof | DENALI THERAPEUTICS, INC. (US) | 2017-10-31 | — | — | US | disclosed |
| US-9802927-B2 | Oxadiazine compounds and methods of use thereof | DENALI THERAPEUTICS, INC. (US) | 2017-10-31 | — | — | US | disclosed |
| US-20170066753-A1 | OXADIAZINE COMPOUNDS AND METHODS OF USE THEREOF | DENALI THERAPEUTICS, INC. | 2017-03-09 | — | — | US | disclosed |
| US-20170066753-A1 | OXADIAZINE COMPOUNDS AND METHODS OF USE THEREOF | DENALI THERAPEUTICS, INC. | 2017-03-09 | — | — | US | disclosed |
| US-20170066753-A1 | OXADIAZINE COMPOUNDS AND METHODS OF USE THEREOF | DENALI THERAPEUTICS, INC. | 2017-03-09 | — | — | US | disclosed |
| WO-2016201168-A1 | OXADIAZINE COMPOUNDS AND METHODS OF USE THEREOF | FORUM PHARMCEUTICALS INC. (US) | 2016-12-15 | — | — | WO | disclosed |
| EP-2323978-A1 | AMIDE COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2011-05-25 | — | — | EP | disclosed |
| WO-2010018874-A1 | AMIDE COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-02-18 | — | — | WO | disclosed |
| US-20100041891-A1 | AMIDE COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-02-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170066753-A1 | OXADIAZINE COMPOUNDS AND METHODS OF USE THEREOF | PSEN2, SMN1; SMN2, OTC | GSK3B 242/4885PTPN1 2744/4885TAS1R3 4860/4885 |
| US-20100041891-A1 | AMIDE COMPOUND | GPR52, GPR132, NR5A2 | GSK3B 3757/4885PTPN1 1300/4885TAS1R3 1244/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.